Page 65 - 2021_09-Haematologica-web

NOTCH1 mutations in CLL
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. J Exp Med. 2018;215 (2):681-697.
8. Pepper C, Hoy T, Bentley P. Elevated Bcl- 2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance. Leuk Lymphoma. 1998;28 (3-4):355-361.
9. Williamson KE, Kelly JD, Hamilton PW, et al. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer. 1998;78(4):553-554.
10. Del Principe MI, Dal Bo M, Bittolo T, et al. Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. Haematologica. 2016;101(1):77-85.
11. Rai KR, Han T. Prognostic factors and clini- cal staging in chronic lymphocytic leukemia. Hematol Oncol Clin North Am. 1990;4(2):447-456.
12. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760.
13. Degan M, Bomben R, Dal Bo M, et al. Analysis of IgV gene mutations in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies sub- groups with different prognosis and usage of the canonical somatic hypermutation machinery. Br J Haematol. 2004;126(1):29- 42.
14. Bomben R, Dal Bo M, Zucchetto A, et al. Mutational status of IgV(H) genes in B-cell chronic lymphocytic leukemia and progno- sis: percent mutations or antigen-driven selection? Leukemia. 2005;19(8):1490-1492.
15. Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high- performance genomics data visualization and exploration. Brief Bioinform. 2013;14 (2):178-192.
16. D'Agaro T, Bittolo T, Bravin V, et al. NOTCH1 mutational status in chronic lym- phocytic leukaemia: clinical relevance of subclonal mutations and mutation types. Br J Haematol. 2018;182(4):597-602.
17. Byrd JC, O'Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(13):1278-1279.
18. Lionetti M, Fabris S, Cutrona G, et al. High- throughput sequencing for the identification of NOTCH1 mutations in early stage chron- ic lymphocytic leukaemia: biological and clinical implications. Br J Haematol. 2014;165(5):629-639.
19. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational acti- vation. J Exp Med. 2011;208(7):1389-1401.
20.Weissmann S, Roller A, Jeromin S, et al.
Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocyt- ic leukemia (CLL): a study on 852 patients. Leukemia. 2013;27(12):2393-2396.
21. Villamor N, Conde L, Martínez-Trillos A, et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia. 2013;27(5): 1100-1106.
22. Sportoletti P, Baldoni S, Del Papa B, et al. A revised NOTCH1 mutation frequency still impacts survival while the allele burden pre- dicts early progression in chronic lympho- cytic leukemia. Leukemia. 2014;28(2):436- 439.
23. Del Poeta G, Dal Bo M, Del Principe MI, et al. Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lym- phocytic leukaemia. Br J Haematol. 2013;160(3):415-418.
24. Oscier DG, Rose-Zerilli MJ, Winkelmann N, et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood. 2013;121(3):468-475.
25. Chiorazzi N, Rai KR, Ferrarini M. Chroniclymphocyticleukemia. N Engl J Med. 2005;352(8):804-815.
26. Pozzo F, Bittolo T, Arruga F, et al. NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dys- regulation. Leukemia. 2016;30(1):182-189.
27. Chiaretti S, Marinelli M, Del Giudice I, et al. NOTCH1, SF3B1, BIRC3 and TP53 muta- tions in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment. Leuk Lymphoma. 2014;55(12):2785-2792.
28. Larrayoz M, Rose-Zerilli MJ, Kadalayil L, et al. Non-coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial. Leukemia. 2017;31(2):510-514.
29. Kantorova B, Malcikova J, Brazdilova K, et al. Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients. Br J Haematol. 2017;178(6):979-982.
30. Del Giudice I, Rossi D, Chiaretti S, et al. NOTCH1 mutations in +12 chronic lym- phocytic leukemia (CLL) confer an unfavor- able prognosis, induce a distinctive tran- scriptional profiling and refine the interme- diate prognosis of +12 CLL. Haematologica. 2012;97(3):437-441.
31. Bulian P, Bomben R, Dal Bo M, et al. Mutational status of IGHV is the most reli- able prognostic marker in trisomy 12 chron- ic lymphocytic leukemia. Haematologica. 2017;102(11):e443-e446.
32. López C, Delgado J, Costa D, et al. Different distribution of NOTCH1 mutations in
chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromo- somal alterations. Genes Chromosomes Cancer. 2012;51(9):881-889.
33. Balatti V, Lerner S, Rizzotto L, et al.Trisomy 12 CLLs progress through NOTCH1 muta- tions. Leukemia. 2013;27(3):740-743.
34. Herman SE, Niemann CU, Farooqui M, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correla- tive analyses from a phase II study. Leukemia. 2014;28(11):2188-2196.
35.Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16(2): 169-176.
36. Strati P, Parikh SA, Chaffee KG, et al. CD49d associates with nodal presentation and sub- sequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2017;178(1):99- 105.
37. Brown JR, Hillmen P, O'Brien S, et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RES- ONATE study in patients with previously treated CLL/SLL. Leukemia. 2018;32(1):83- 91.
38. Dal Bo M, Del Principe MI, Pozzo F, et al. NOTCH1 mutations identify a chronic lym- phocytic leukemia patient subset with worse prognosis in the setting of a ritux- imab-based induction and consolidation treatment. Ann Hematol. 2014;93(10):1765- 1774.
39. Del Poeta G, Del Principe M, Postorino M, et al. Apoptosis resistance and NOTCH1 mutations impair clinical outcome in chron- ic lymphocytic leukemia (CLL) patients treated with ibrutinib. Blood. 2017;130 (Suppl 1):261.
40. Guièze R, Robbe P, Clifford R, et al. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. Blood. 2015;126(18):2110-2117.
41. Baliakas P, Hadzidimitriou A, Sutton LA, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015;29(2):329-336.
42. Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. 2012;119(2):521-529.
43. López-Guerra M, Xargay-Torrent S, Rosich L, et al. The γ-secretase inhibitor PF- 03084014 combined with fludarabine antag- onizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells. Leukemia. 2015;29(1):96-106.
44.Wu Y, Cain-Hom C, Choy L, et al. Therapeutic antibody targeting of individual Notch receptors. Nature. 2010;464(7291): 1052-1057.
haematologica | 2021; 106(9)
2353